The following antibodies were used: monoclonal anti-bromodeoxyuridine (BrdU; clone BU33, 1:2000; Sigma), a neutralizing rabbit anti-human EGF antibody (polyclonal, 1:250; Chemicon International, Temecula, CA), a polyclonal neutralizing antibody directed against natural human PDGF (20 μg/mL; Calbiochem), a polyclonal antibody directed against the human and rat PDGF-B chain (10 μg/mL; Calbiochem), a neutralizing anti-human heparin binding (HB)-EGF (polyclonal, 5 μg/mL; Calbiochem), a monoclonal neutralizing anti-MMP9 (10 μg/mL, Calbiochem), a polyclonal rabbit anti-rat p44/p42 MAPK (New England Biolabs, Frankfurt-am-Main, Germany; 1:1000), a polyclonal rabbit anti-phosphorylated MAPK (Promega, Madison, WI; 1:5000), a polyclonal rabbit anti-human EGF receptor (Santa Cruz Biotechnology, Heidelberg, Germany; 1:200), a polyclonal rabbit anti-human-phosphorylated EGF receptor (Tyr1045) antibody (1:1000; New England Biolabs), a polyclonal rabbit anti-human p38 MAPK (1:1000; New England Biolabs), a polyclonal rabbit anti-human-phosphorylated p38 MAPK (1:1000; New England Biolabs), Cy3-conjugated goat anti-mouse secondary antibody (1:400; Jackson ImmunoResearch Laboratory, West Grove, PA), a secondary biotinylated anti-rabbit IgG (Vector Laboratories, Burlingame, CA), and a secondary anti-rabbit IgG conjugated with alkaline phosphatase (Sigma; 1:5000).